DK3371150T3 - Fremgangsmåde til at fremstille brivaracetam - Google Patents

Fremgangsmåde til at fremstille brivaracetam Download PDF

Info

Publication number
DK3371150T3
DK3371150T3 DK16787866.9T DK16787866T DK3371150T3 DK 3371150 T3 DK3371150 T3 DK 3371150T3 DK 16787866 T DK16787866 T DK 16787866T DK 3371150 T3 DK3371150 T3 DK 3371150T3
Authority
DK
Denmark
Prior art keywords
fremstille
brivaracetam
fremgangsmåde til
fremgangsmåde
til
Prior art date
Application number
DK16787866.9T
Other languages
English (en)
Inventor
Thierry Defrance
Didier Nuel
Jean Septavaux
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Application granted granted Critical
Publication of DK3371150T3 publication Critical patent/DK3371150T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16787866.9T 2015-11-03 2016-10-27 Fremgangsmåde til at fremstille brivaracetam DK3371150T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15192760 2015-11-03
PCT/EP2016/075935 WO2017076738A1 (en) 2015-11-03 2016-10-27 Process for preparing brivaracetam

Publications (1)

Publication Number Publication Date
DK3371150T3 true DK3371150T3 (en) 2021-11-15

Family

ID=54476761

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16787866.9T DK3371150T3 (en) 2015-11-03 2016-10-27 Fremgangsmåde til at fremstille brivaracetam

Country Status (13)

Country Link
US (1) US10421717B2 (da)
EP (1) EP3371150B1 (da)
CY (1) CY1124587T1 (da)
DK (1) DK3371150T3 (da)
ES (1) ES2893301T3 (da)
HR (1) HRP20211518T1 (da)
HU (1) HUE056380T2 (da)
LT (1) LT3371150T (da)
PL (1) PL3371150T3 (da)
PT (1) PT3371150T (da)
RS (1) RS62472B1 (da)
SI (1) SI3371150T1 (da)
WO (1) WO2017076738A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240027T1 (hr) 2015-05-25 2024-04-26 Suzhou Pengxu Pharmatech Co., Ltd. Postupci za proizvodnju brivaracetama
WO2018220646A1 (en) * 2017-05-29 2018-12-06 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereof
CN108101823A (zh) * 2018-02-13 2018-06-01 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
CN108101824B (zh) * 2018-02-13 2020-04-03 扬州奥锐特药业有限公司 一种高手性纯度内酰胺中间体及布瓦西坦的制备方法
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN111333563B (zh) 2018-12-19 2023-11-07 上海科胜药物研发有限公司 一种布瓦西坦中间体的制备方法
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN111187175A (zh) * 2020-01-08 2020-05-22 上海朴颐化学科技有限公司 一种利用微通道反应器氢化制备布瓦西坦的中间体的方法
LV15614A (lv) 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
CN114394921A (zh) * 2022-02-22 2022-04-26 浙江九洲药业股份有限公司 一种高纯度布瓦西坦的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
PL1667967T3 (pl) 2003-09-24 2012-11-30 Ucb Pharma Sa Sposób wytwarzania pochodnych 2-okso-1-pirolidyny
EP2053040A1 (en) 2007-10-26 2009-04-29 Chemo Ibérica, S.A. Pregabalin intermediates and process for preparing them and Pregabalin

Also Published As

Publication number Publication date
EP3371150A1 (en) 2018-09-12
PT3371150T (pt) 2021-11-05
PL3371150T3 (pl) 2022-01-17
LT3371150T (lt) 2021-11-25
US10421717B2 (en) 2019-09-24
HUE056380T2 (hu) 2022-02-28
RS62472B1 (sr) 2021-11-30
SI3371150T1 (sl) 2021-11-30
HRP20211518T1 (hr) 2021-12-24
EP3371150B1 (en) 2021-08-18
ES2893301T3 (es) 2022-02-08
WO2017076738A1 (en) 2017-05-11
CY1124587T1 (el) 2022-07-22
US20190119206A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
DK3506981T3 (en) Et transportabelt automatiseret eksternt defibrillator-apparat til engangsbrug
DK3410992T3 (en) Tilbagetrækkeligt udløb til stomipose
DK3386454T3 (en) Forbinding til hudpleje i fugtigt miljø
DK3325223T3 (en) Tandhjulspakke til robotarme
DK3770053T3 (en) Batterilås til en elcykel
DK3371150T3 (en) Fremgangsmåde til at fremstille brivaracetam
AU366876S (en) Cap
DK3347540T3 (en) Bærer til et lineært loftspanel
DK3343955T3 (en) Anordning til et høreapparat
DK3456957T3 (en) Modvægtssystem til balanceret navvindmølleinstallation
DK3457555T3 (en) Drev til et transportsystem
DK3688240T3 (en) Konstruktionssystem til et bygningsmodul
DK2982407T3 (en) Trinfuntion til styrbare føringstråde
DK3259217T3 (en) Transportsystem til blodprøver
DK3726976T3 (en) Klimareguleringssystem til insektopdræt
DK3481437T3 (en) Precursorer til radiofluorering
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3264929T3 (en) Tilpasningsdygtigt fodtøj til fodboldspil
DK3655755T3 (en) Effektorapparat til vandpotentiale i jord
DK3430280T3 (en) Magnetisk leje til en turbomaskine
DK3250312T3 (en) Urea-metalnitrat-scr-system
DK3558418T3 (en) Et infusionssystem til kortlivede radiofarmaceutika
DK3242882T3 (en) Cgrp-antagonistpeptider
DK3607709T3 (en) Switch-Proxy-kontrolenhed til switch-virtualisering